A5100628586- Diabetes Management and Research
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Statistical Methods in Clinical Trials
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Diabetes Management and Education
- Metabolism, Diabetes, and Cancer
- Gestational Diabetes Research and Management
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Neurological Disorders and Treatments
- Cardiovascular Health and Risk Factors
- Oral health in cancer treatment
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Diet and metabolism studies
- Liver Disease Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- MicroRNA in disease regulation
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Advanced Causal Inference Techniques
Hebei Medical University
2025
Fourth Hospital of Hebei Medical University
2025
Nanjing University of Chinese Medicine
2023-2024
Third Affiliated Hospital of Sun Yat-sen University
2013-2024
Sun Yat-sen University
2009-2024
Huzhou University
2014-2024
Zhaoqing University
2024
Shijiazhuang Tiedao University
2024
Southeast University
2022-2023
Suzhou Traditional Chinese Medicine Hospital
2023
NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, reversible dual TKI, (L+C) in patients with centrally confirmed HER2-positive, metastatic breast cancer (MBC) ≥ 2 previous HER2-directed MBC regimens.Patients, including those stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day)...
To investigate the effect of antidiabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM), 75 T2DM and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add‐on liraglutide, sitagliptin, or insulin glargine this 26‐week trial. The primary endpoint was change intrahepatic lipid (IHL) from baseline week 26 as quantified magnetic resonance imaging–estimated proton density fat fraction (MRI‐PDFF). Secondary...
OBJECTIVE—To investigate whether long-term optimal glycemic control can be achieved without medication by transient continuous subcutaneous insulin infusion (CSII) and the possible mechanisms responsible for this remission. RESEARCH DESIGN AND METHODS—Newly diagnosed type 2 diabetic patients (n = 138, fasting glucose >11.1mmol/l) were hospitalized treated with CSII weeks. Intravenous tolerance tests (IVGTTs) performed, blood glucose, HbA1c, lipid profiles, proinsulin, insulin,...
We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3; platelet-derived receptor; Kit) combined with carboplatin/paclitaxel improved overall survival (OS) versus chemotherapy alone in patients nonsquamous non-small-cell lung cancer (NSCLC) the subset adenocarcinoma.Patients stage IIIB/IV or recurrent NSCLC (no prior systemic therapy for advanced disease) were randomly assigned 1:1 to carboplatin (area under curve, 6 mg/ml ·...
Abstract BACKGROUND: It has been reported that antidiabetic drugs affect the risk of cancer and prognosis patients with diabetes, but few studies have demonstrated influence different agents on outcomes after anticancer therapy among cancer. The objective this study was to evaluate metformin insulin advanced nonsmall cell lung (NSCLC) plus type 2 diabetes who received first‐line chemotherapy. METHODS: Data NSCLC had from 5 hospitals in China during January 2004 March 2009 were reviewed...
Purpose: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients metastatic colorectal cancer. Patients and Methods: (N = 81) received KGF by intravenous (IV) bolus on days 1 to 3, followed FU 425 mg/m 2 /d IV plus leucovorin 20 4 8. dose levels were 1, 10, 20, 40, 60, 80 μg/kg/d. A randomized, placebo-controlled design was employed (2:1 randomization placebo). Oral mucositis assessed examination 4, 8, 15, 28. In...
Monitoring patient safety during clinical trials is a critical component throughout the drug development life-cycle. Pharmaceutical sponsors must work proactively and collaboratively with all stakeholders to ensure systematic approach monitoring. The regulatory landscape has evolved increased requirements for risk management plans, evaluation minimization strategies. As industry transitions from passive active surveillance activities, there will be greater demand more comprehensive...
Oogenesis is a fundamental process of human reproduction, and mitochondria play crucial roles in oocyte competence. Mitochondrial ATP-dependent Lon protease 1 (LONP1) functions as critical protein maintaining mitochondrial cellular homeostasis somatic cells. However, the essential role LONP1 mammalian oogenesis far from elucidated.Using conditional Lonp1-knockout mice, RNA sequencing (RNA-seq) coimmunoprecipitation/liquid chromatography-mass spectrometry (Co-IP/LC-MS) technology, we analysed...
We propose a group sequential Holm procedure when there are multiple primary endpoints. This method addresses multiplicities arising from endpoints and analyses in design. It has been shown to be closed testing preserves the familywise error rate strong sense. When only concern without an interim analysis, simplifies weighted procedure. The proposed is more powerful than parallel avoids need anticipate order as fixed sequence scheme.
MicroRNA-613 (miR-613) plays important roles in tumorigenesis and cancer progression. We aimed to evaluate its expression level potential for diagnosis prognosis esophageal squamous cell (ESCC). examined miR-613 60 pairs of ESCC cancerous matched paracancerous tissues, serum samples from 75 patients healthy volunteers, 105 formalin-fixed paraffin-embedded (FFPE) tissue using quantitative reverse transcription polymerase chain reaction. Receiver-operating characteristic (ROC) curve analysis,...
Glycaemic control is a great challenge in the management of type 1 diabetes mellitus (T1DM). There limited data concerning glycaemic among adults with T1DM. We used from Guangdong T1DM Translational Medicine Study to evaluate and its associated factors Chinese T1DM.This cross-sectional analysis included 827 participants who were 18 years age or older had been living for at least year. Participants HbA1c levels <7% compared against those ≥ 7%. A multivariate logistic regression model was...
Adenovirus (Ad)-based antiangiogenesis gene therapy is a promising approach for cancer treatment. Downregulation or loss of coxsackievirus and adenovirus receptor (CAR) often detected in various human cancers, which hampers adenoviral approaches. Cationic liposome-complexed vectors have been proven useful CAR-deficient cells to enhance therapeutic transfer vivo. Here, we investigated the antitumor effects recombinant encoding endostatin (Ad-hE) encapsulated cationic liposome (Ad-hE/Lipo) on...
LBA7512 Background: This study evaluated whether motesanib (a selective oral inhibitor of VEGFR 1, 2 and 3; PDGFR Kit) plus C/P improved overall survival (OS) compared with placebo + in patients (pts) nonsquamous NSCLC a subset pts adenocarcinoma. Methods: Pts had stage IIIB/IV or recurrent no prior systemic therapy for advanced NSCLC. The initially enrolled all histologies but was amended to exclude squamous owing high rate hemoptysis. were randomized 1:1 receive up six 3-wk cycles C (AUC 6...
Abnormal paired box 9 (PAX9) expression is associated with tumorigenesis, cancer development, invasion and metastasis. The present study investigated the prognostic significance of PAX9 in esophageal squamous cell carcinoma (ESCC) its role predicting radiation sensitivity. A total 52.8% (121/229) ESCC tissues were positive for PAX9. 1‑, 3‑ 5‑year disease‑free survival (DFS) rates 72.2, 35.2 5.6%, respectively, overall (OS) 86.1, 44.4, 23.1%, PAX9‑positive tumors. In PAX9‑negative tumors,...
Abstract Context New strategies and biomarkers are needed in the early detection of β-cell damage progress type 1 diabetes mellitus (T1DM). Objective To explore whether serum microRNAs (miRNA) should be served as for T1DM. Design, Settings, Patients The miRNA profile was established with microarray discovery phase (six T1DM, six controls). A miRNA-based model T1DM diagnosis developed using logistic regression analysis training dataset (40 56 controls) then validated leave-one-out cross...
Abstract Aims/hypothesis The study aimed to investigate the effects of HLA class I genes on susceptibility type 1 diabetes with different onset ages, in addition well-established II genes. Methods A total 361 patients (192 <18 years and 169 ≥18 years) 500 healthy control participants from China were enrolled genotyped for HLA-A , -B -C -DQA1 -DQB1 -DRB1 using next-generation sequencing. Results susceptible DR3 (β = −0.09, p 0.0009) DR4-DQ8 −0.13, 0.0059) haplotypes negatively associated...
Our aim was to investigate the impact of glycemic variability (GV) on relationship between glucose management indicator (GMI) and laboratory glycated hemoglobin A1c (HbA1c).Adult patients with type 1 diabetes mellitus (T1D) were enrolled from five hospitals in China. All subjects wore iPro™2 system for 14 days before HbA1c measured at baseline, 3 months 6 months. Data derived sensor used calculate GMI GV parameters [standard deviation (SD), coefficient variation (CV), mean amplitude...